The vktx stock price's 50-day moving average has just crossed above its 200-day average — a “golden cross” signal favored by trend-following investors. This could imply medium-term strength in Viking Therapeutics’ equity. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Beyond fundamentals, Viking is widely viewed as a buyout target given the projected $50–100 billion GLP market by 2030, with even a third entrant poised to capture meaningful share. The ability of VK2735 to enable rapid initial weight loss with high doses and transition patients to oral maintenance regimens without injections makes it uniquely compelling. Taken together, VKTX offers asymmetric upside, with catalysts ranging from clinical milestones to M&A, and potential 5x returns over the next year. Momentum indicators remain constructive.